Directors Dealings
Director dealings are proprietary transactions by executives, which are reportable under Art. 19 MAR. The publication of these transactions is an important contribution to the prevention of insider dealing and market manipulation. In addition, knowledge of such transactions is of great importance to the market, as these transactions provide indications of management's assessment of the company's future business prospects. The information presented here relates to companies that are under the supervision of BaFin.
Symrise AG: A reportable insider transaction was published on 6th August 2025. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 6th August 2025,
The Insider Transaction was made by Pfeifer, Prof. Dr. Andrea 
. The transaction toke place on 6th August 2025. The order was executed at the trading place LGT Bank AG. . The aggregated volume was 40.770,54 EUR, based on an average price of 80,34 EUR. The nature of the Investment was Buy.
FUCHS SE: A reportable insider transaction was published on 4th August 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 4th August 2025,
The Insider Transaction was made by Fuchs, Stefan . The transaction toke place on 31st July 2025. The order was executed at the trading place XETRA - REGULIERTER MARKT. . The aggregated volume was 295.385,00 EUR, based on an average price of 31,42 EUR. The nature of the Investment was Buy.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Heidelberg Pharma AG: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by Pahl, Prof. Dr. Andreas . The transaction toke place on 23rd July 2025. . The aggregated volume was 170.100,00 EUR, based on an average price of 1,89 EUR. The nature of the Investment was not specified.
Leifheit Aktiengesellschaft: A reportable insider transaction was published on 1st July 2025. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 1st July 2025,
The Insider Transaction was made by De Loecker, Stefan . The transaction toke place on 30th June 2025. . The aggregated volume was 123.000,00 EUR, based on an average price of 16,40 EUR. The nature of the Investment was Buy.
FUCHS SE: A reportable insider transaction was published on 6th June 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 6th June 2025,
The Insider Transaction was made by Fuchs, Stefan . The transaction toke place on 5th June 2025. The order was executed at the trading place XETRA. . The aggregated volume was 387.778,04 EUR, based on an average price of 48,20 EUR. The nature of the Investment was Sell.
Your Family Entertainment Aktiengesellschaft: A reportable insider transaction was published on 15th May 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 15th May 2025,
The Insider Transaction was made by Piëch, Dr. Stefan . The transaction toke place on 12th May 2025. The order was executed at the trading place Xetra. . The aggregated volume was 2.400,00 EUR, based on an average price of 1,20 EUR. The nature of the Investment was Buy.
BASF SE: A reportable insider transaction was published on 7th May 2025. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 7th May 2025,
The Insider Transaction was made by Asenkerschbaumer, Prof. Dr. Stefan . The transaction toke place on 5th May 2025. The order was executed at the trading place XETRA. . The aggregated volume was 74.981,41 EUR, based on an average price of 42,43 EUR. The nature of the Investment was Buy.
BASF SE: A reportable insider transaction was published on 7th May 2025. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 7th May 2025,
The Insider Transaction was made by Carell, Prof. Dr. Thomas . The transaction toke place on 5th May 2025. The order was executed at the trading place XETRA. . The aggregated volume was 49.987,61 EUR, based on an average price of 42,43 EUR. The nature of the Investment was Buy.
Nexus AG: A reportable insider transaction was published on 17th April 2025. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 17th April 2025,
The Insider Transaction was made by Rosenthal, Prof. Dr. Felicia . The transaction toke place on 14th April 2025. . The aggregated volume was 29.750,00 EUR, based on an average price of 70,00 EUR. The nature of the Investment was Sell.
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.